Bausch Health Companies
BHC NYSE· Pharmaceuticals
Last close · Oct 26, 2026
$6.35
KIRA · Stoqly’s AI analyst, in plain words
- Bausch Health Companies had $10.3B of revenue in fiscal 2025, up 6.7% on the year before. Over five years, revenue changed +5.0% a year on average.
- Its operating margin was 17.7%, up 1.6 pts: of every 100 in sales, about 18 is left after running the business.
- Bausch Health Companies made $157M of net profit in fiscal 2025.
- Free cash flow was $1.0B in fiscal 2025, 9.8% of revenue.
- Bausch Health Companies returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 1.9%.
- Bausch Health Companies owes $19.5B more than it holds in cash, about 6.5 years of operating profit.
Market cap
$2.4B
P/E
—
Revenue
$10.3B
Net income
$157M
Free cash flow
$1.0B
Operating margin
17.7%
Bausch Health Companies in 30 seconds · fiscal 2025
Are sales growing?
+6.7%
Yes. Sales grew 6.7% last year.
Does it make a profit?
1.5%
A little. It keeps 1.5% of every sale as profit.
Does profit turn into cash?
9.8%
Partly. 9.8% of sales ends up as free cash.
Is debt under control?
6.5x
Heavy. Repaying its debt would take 6.5 years of operating profit.
How healthy are the accounts?
7 / 8
Solid. It passes 7 of 8 health tests.
What Bausch Health Companies does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- Bausch Health Companies Inc.
- CIK
- 0000885590
Bausch Health Companies · BHC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $8.4B | $8.1B | $8.8B | $9.6B | $10.3B |
| Revenue growth | 5.1% | −3.7% | 7.8% | 9.9% | 6.7% |
| Operating margin | 5.3% | 5.6% | 11.0% | 16.1% | 17.7% |
| Net income | −$948M | −$225M | −$592M | −$46.0M | $157M |
| Net margin | −11.2% | −2.8% | −6.8% | −0.5% | 1.5% |
| Diluted EPS | −$2.64 | −$0.62 | −$1.62 | −$0.13 | $0.42 |
| Cash | |||||
| Cash from operations | $1.4B | −$728M | $1.0B | $1.6B | $1.4B |
| Capital expenditure | $269M | $218M | $215M | $337M | $397M |
| Free cash flow | $1.2B | −$946M | $817M | $1.3B | $1.0B |
| FCF margin | 13.7% | −11.6% | 9.3% | 13.1% | 9.8% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share count change | 1.1% | 0.9% | 0.8% | 0.9% | 1.9% |
| Debt and strength | |||||
| Cash and short-term investments | $582M | $564M | $947M | $1.2B | $1.3B |
| Debt incl. finance leases | $22.7B | $20.8B | $22.4B | $21.6B | $20.8B |
| Shareholders' equity | −$106M | −$692M | −$1.0B | −$1.3B | −$554M |
| Net debt / EBITDA | 11.0x | 10.9x | 9.6x | 7.3x | 6.5x |
| Current ratio | 1.1x | 1.1x | 1.3x | 0.9x | 1.5x |
| Interest coverage | 0.3x | 0.3x | 0.7x | 1.1x | 1.1x |
| Returns and quality | |||||
| Return on capital | 1.6% | 1.7% | 3.6% | 3.7% | 4.5% |
| Piotroski F-score | 3 | 2 | 4 | 5 | 7 |
| Altman Z'' | −0.8 | −1.0 | −0.6 | −1.1 | −0.2 |
Insiders bought, 12 months
$15.6M
1 insider
Insiders sold, 12 months
$0.5M
3 insiders
Of sales under plans
100%
$0.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bausch Health Companies · BHC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Bausch Health Companies BHC | $2.4B | 6.7% | 17.7% | 9.8% | 4.5% | — | 7 |
| Zoetis ZTS | $33.8B | 2.3% | — | 24.1% | 29.3% | 13.3x | 8 |
| Viatris VTRS | $21.3B | −3.0% | −18.6% | 13.6% | −7.1% | — | 4 |
| Teva Pharmaceuticals TEVA | $46.5B | 4.3% | 12.5% | 6.7% | 10.5% | 66.6x | 8 |
| Elanco ELAN | $11.6B | 6.2% | — | 6.0% | −0.1% | — | 6 |
KIRA
At $6.35 a share, the company is worth $2.4B.
Bausch Health Companies grew sales faster than 4 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0000885590). Data updated October 23, 2026. For information only — not investment advice. Check the original filings before relying on any figure.